[1] [2] [3] Go to: Etiology Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication of antipsychotic drug therapy
, antipsychotic medications) and is manifest by mental status changes, hyperthermia, rigidity, and autonomic dysfunction
Stiff, rigid muscles that can lead to eventual Neuroleptic malignant syndrome, a rare but potentially fatal side effect of antipsychotic medications, has often proven refractory to conventional antiparkinsonian medications
Response to therapy was assessed by monitoring vital signs and serum creatine kinase (CK) levels
— We read the article of Mueller et al reporting successful treatment of the neuroleptic malignant syndrome (NMS) with bromocriptine mesylate (1983;249:386)
These cases were categorized into four treatment groups We present the first case report of neuroleptic malignant syndrome associated with the withdrawal of bromocriptine
Two patients with NMS are presented: the first treated in the usual fashion in the medical intensive care unit (ICU), the second on the psychiatric ward, with the rapidly successful and first reported usage of bromocriptine mesylate
Authors W M Verhoeven, A Elderson, H G Westenberg PMID: 3995115 DOI: 10
1983 Jan 21;249(3):386-8
Although estimates of the incidence of NMS once ran as high as 3% of patients treated with antipsychotics Introduction: The neuroleptic malignant syndrome (NMS) is a potentially life-threatening condition associated to the use of antipsychotics
Dopamine agonists are also prescribed to counteract dopamine antagonist-induced hyperprolactinemia
The classic presentation is that of hyperpyrexia, muscle rigidity, mental state changes and autonomic instability
NMS is a rare adverse drug reaction, with a complex pathophysiology and presentation
NMS often occurs shortly after the initiation of neuroleptic treatment, or after dose increases
Symptoms include: In most cases, the disorder develops within the first two weeks of treatment with the drug; however, the disorder may develop at any time during the therapy period
In mild to moderate NMS, symptomatic therapy might be sufficient
Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening sideeffect that can occur in response to treatment with antipsychotic drugs
The incidence of NMS with conventional antipsychotics has been shown to be anywhere from 0
(2) NMS usually develops over days or weeks
1,2 It is characterised by severe rigidity, tremor, fever Neuroleptic malignant syndrome (NMS) is an uncommon but serious adverse event to antipsychotic medications
Malignant syndrome is a potentially fatal condition and awareness of this Scope and Nature of Neuroleptic Malignant Syndrome
After the diagnosis of NMS was made, all neuroleptics were discontinued, and the patient began therapy with dantrolene sodium and bromocriptine
Neuroleptic medications are antipsychotic medications, including typical Catatonia is a syndrome, comprised of symptoms such as motor immobility, excessive motor activity, extreme negativism, and stereotyped movements
The efficacy of these agents for treating NMS is based upon expert opinion, and not upon In patients with neuroleptic malignant syndrome, the causative drug is stopped and complications are treated supportively, usually in an intensive care unit (ICU) (1 Key Points Neuroleptic malignant syndrome is characterized by altered mental status, muscle rigidity, hyperthermia, and autonomic hyperactivity that occur when certain neuroleptic drugs are used
10
Treatment begins with cessation of the causative agent, and also may include aggressive T2 - Successful treatment with dantrolene and bromocriptine
The empiric medications most frequently used for refractory NMS include bromocriptine mesylate, a dopamine agonist, and dantrolene sodium, a muscle relaxant
5 mg three times a day and can be titrated upwards to 45 mg per day Neuroleptic malignant syndrome (NMS) is characterized by distinctive clinical features such as altered mental status, muscular rigidity, hyperpyrexia, and dysautonomia [ 1 ]
J
syndrome whose condition improved dramatically with the addition of the anticholinergic drug benztropine after initial treatment with bromocriptine
03 days) significantly shortened the time to clinical response
Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal idiosyncratic complication of antipsychotic drug therapy
See more The empiric medications most frequently used for refractory NMS include bromocriptine mesylate, a dopamine agonist, and
Five patients with neuroleptic malignant syndrome were treated with bromocriptine mesylate 7
We read the article of Mueller et al reporting successful treatment of the neuroleptic malignant syndrome (NMS) with bromocriptine mesylate (1983;249:386)
Neuroleptic malignant syndrome (NMS) is a serious iatrogenic condition
NMS is observed mainly in patients treated with neuroleptics, especially with high-potency neuroleptics, atypical neuroleptics, low-potency D2-receptor antagonists
1016/0006-3223(85)90104-0
Bromocriptine / therapeutic use* Diagnosis, Differential Female Fever / chemically induced Humans Male The aim of this chapter is to review two of the most common drug-induced hyperthermic states, serotonin syndrome and neuroleptic malignant syndrome
Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine Ann Neurol
Neuroleptic malignant syndrome (NMS) is a rare and life-threatening reaction to the use of any neuroleptic medication
Neuroleptic malignant syndrome (NMS) is a potentially fatal syndrome which is rarely seen during treatment with antipsychotic medications
We present the first case report of neuroleptic malignant syndrome associated with the withdrawal of bromocriptine
exhaustion
It is a relatively rare, but potentially lethal complication, the incidence of which may have been underestimated
Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening sideeffect that can occur in response to treatment with antipsychotic drugs
doi: 10
The incidence of NMS with conventional antipsychotics has been shown to be anywhere from 0
NMS: Bromocriptine, amantadine & dantrolene have been used as treatments for Neuroleptic Malignant Syndrome (NMS), a potentially lethal side effect associated with the use of drugs that block dopamine receptors (the highest incidence is associated with high potency antipsychotics such as haloperidol)
Treatment involves immediately discontinuing the offending agent, aggressive supportive care to manage and prevent complications, and pharmacologic therapy in severe cases
After the diagnosis of NMS was made, all neuroleptics were discontinued, and the patient began therapy with dantrolene sodium and bromocriptine
In mild to moderate NMS, symptomatic therapy might be sufficient